ALFA Finder| Margins | EBITDA before R&D margin at 24%; Net Profit Margin at 8%. |
|---|---|
| Order book | API segment bolstered by strong order book. |
| Demand visibility | Strong order book supporting 33% API growth. |
Growth
Revenue grew 26% to INR 21.50 Bn. EBITDA after R&D rose 21% YoY, while PAT grew 12% to INR 1.73 Bn.
Outlook
Pipeline includes 15+ US launches for FY27. Targets Water Neutrality and 50,000 trees by 2027; Net Zero by 2050.
Risks
Industry-wide interest rate and currency fluctuations; regulatory approvals; patent challenges; and manufacturing/marketing risks for approved products.
Investor Presentation filed with NSE, NSE: APLLTD. Summary written with AI assistance from the document.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,030.15
- Market cap
- ₹20,249 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.0×Sector 43.7×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.2 Cr · +81.5% YoY